Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Memantine Hydrochloride,Donepezil
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Receives FDA Approval for Memantine/Donepezil and Tentative Approval for Rifaximin
Details : A generic combination of memantine HCl extended-release, a NMDA receptor antagonist, and donepezil HCl, an acetylcholinesterase inhibitor, is approved for dementia of the Alzheimer’s.
Product Name : Namzaric
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 23, 2025
Lead Product(s) : Memantine Hydrochloride,Donepezil
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Donepezil
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADLARITY (donepezil transdermal system) developed by Corium, is the first and only U.S. FDA approved once-weekly, donepezil transdermal system for patients with mild, moderate and severe dementia of the Alzheimer's type.
Product Name : Adlarity
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 12, 2023
Lead Product(s) : Donepezil
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Donepezil
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Lotus Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Lotus will have exclusive rights to commercialize Adlarity (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in the applicable territory and will be responsible for the regulatory approval p...
Product Name : Adlarity
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 10, 2023
Lead Product(s) : Donepezil
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Lotus Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Suven Life Sciences Breathes New Life Into Drug Discovery Plans
Details : SUVN-502 (masupirdine) is a novel, potent, pure, and orally active 5-HT6 receptor antagonist, it is being investigated as a potential therapy against alzheimer's disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 11, 2023
Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Donepezil,Memantine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study
Details : Cognic (donepezil) is a transactive response DNA binding protein of 43 kDa (TDP-43) is involved in regulation of gene expression. AD patients with TDP-43 pathology have increased severity of cognitive impairment compared to those without TDP-43 pathology...
Product Name : Cognic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 19, 2023
Lead Product(s) : Donepezil,Memantine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Donepezil
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results of Study 419 did not show statistically significant difference in efficacy between placebo and Aricept (donepezil hydrochloride) groups at time of final analysis in primary endpoint, CIBIC-plus comprehensive assessment.
Product Name : Aricept
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 29, 2022
Lead Product(s) : Donepezil
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Donepezil
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADLARITY is the first and only once-weekly patch to continuously deliver consistent doses of donepezil through the skin. Donepezil is the most prescribed medication in a class of Alzheimer's drugs known as acetylcholinesterase inhibitors.
Product Name : Adlarity
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2022
Lead Product(s) : Donepezil
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Donepezil
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Corium
Deal Size : $2.0 million
Deal Type : Agreement
Details : KemPharm is due to receive the fee, within 30 days following FDA approval of ADLARITY, pursuant to a master development services agreement entered into with Corium in July 2020, under which KemPharm provided development related to Corium’s resubmission...
Product Name : Adlarity
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 16, 2022
Lead Product(s) : Donepezil
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Corium
Deal Size : $2.0 million
Deal Type : Agreement
Lead Product(s) : Donepezil
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The approval of ADLARITY (donepezil transdermal system) reinforces the value of Corium's innovative CORPLEX technology, our CNS expertise, and our mission to deliver solutions that transform care for the Alzheimer's community and others impacted by CNS d...
Product Name : Adlarity
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 14, 2022
Lead Product(s) : Donepezil
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Donepezil
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Clinical Trial of DA-5207 in Healthy Adults
Details : Donepezil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 19, 2021
Lead Product(s) : Donepezil
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable